Patch Test Results With the European Baseline Series, 2021/2022—Joint European Results of the ESSCA A and the EBS B Working Groups of the ESCD , and the GEIDAC C
Contact Dermatitis · 2026
DOI: 10.1111/cod.70134 ↗At a glance
Journal article in Contact Dermatitis, 2026. Written by Wolfgang Uter and 22 co-authors. Institution: Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. Major MEDLINE topics: Patch Tests, Dermatitis, Allergic Contact, Allergens. Cited 2 times so far (Crossref); 102 references. The full text is freely available (open access, CC BY 4.0). Funded by: Fundación Piel Sana, Agencia Española de Medicamentos y Productos Sanitarios, Sanofi España.
Abstract (original language)
Background
Patch test results obtained with the European Baseline Series (EBS) in its current version serve both contact allergy surveillance and (re‐)assessing the diagnostic value of EBS allergens.
Objectives
To present results of current EBS patch testing, obtained in 59 departments in 14 European countries during 2021 and 2022.
Methods
Anonymised or pseudonymised individual data, and partly aggregated results, on demographic/clinical characteristics and patch test results with the EBS were prospectively collected, centrally pooled, and retrospectively analysed.
Results
In 2021 and 2022, 18 832 patients were patch tested with the EBS. Sensitization to nickel remained most common (18.85 (18.29–19.43)% positivity (95% confidence interval)). Fragrance mix I and Myroxylon pereirae resin yielded very similar results with 6.39 (6.04–6.76)% and 6.5 (6.15–6.87)% positivity, respectively. Concerning preservatives, methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) 0.02% aq. yielded 5.52 (5.11–5.96)% and MI 0.2% aq. yielded 5.28 (4.94–5.64)% positives. Testing formaldehyde 2% aq. identified almost one percentage point more positive reactions than 1% aq. (2.05 (1.81–2.32)% vs. 1.22 (0.99–1.48)). Positive reactions to the recently added allergens were most frequently seen to propolis (5.47 (5.12–5.84)%) and 2‐hydroxyethyl methacrylate (3.63 (3.32–3.96)%).
Conclusions
Compared to the previous reporting period, surveillance results with the EBS were mostly stable. The results regarding Quaternium 15 (0.4 (0.29–0.53)% positives) justified its exclusion from the 2023 EBS version.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- Dermatology Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
- Department of Dermatology, University Hospital Antwerp (UZA) and Research Group Immunology, Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium.
- Department of Dermatology, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.
- Complejo Hospitalario Universitario Insular Materno Infantil, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.
- Institute for Interdisciplinary Dermatologic Prevention and Rehabilitation (iDerm) at the Osnabrück University, Osnabrück, Germany.
ORCID profiles: Wolfgang Uter, S Mark Wilkinson, Olivier Aerts, Andrea Bauer, Leopoldo Borrego, Richard Brans, Timo Buhl, Heinrich Dickel, Aleksandra Dugonik, Francesca Larese Filon, Ana Giménez Arnau, Cataldo Patruno, Györgyi Pónyai, Stamatis Gregoriou, Steffen Schubert, Dagmar Simon, Luca Stingeni, Skaidra Valiukevičienė, Elke Weisshaar, Thomas Werfel, Margarida Gonçalo, Marie-L A Schuttelaar
Funding
- Fundación Piel Sana
- Agencia Española de Medicamentos y Productos Sanitarios
- Sanofi España
- LEO Pharma
Cite
APA
Uter, W., Wilkinson, S. M., Aerts, O., Bauer, A., Borrego, L., Brans, R., Buhl, T., Dickel, H., Dugonik, A., Filon, F. L., Arnau, A. G., Patruno, C., Pónyai, G., Gregoriou, S., Schubert, S., Simon, D., Stingeni, L., Valiukevičienė, S., Weisshaar, E., …, & ESSCAA and EBSB ESCD Working Groups, and the GEIDACC (2026). Patch Test Results With the European Baseline Series, 2021/2022—Joint European Results of the ESSCA A and the EBS B Working Groups of the ESCD , and the GEIDAC C. Contact Dermatitis. https://doi.org/10.1111/cod.70134
Vancouver
Uter W, Wilkinson SM, Aerts O, Bauer A, Borrego L, Brans R, et al. Patch Test Results With the European Baseline Series, 2021/2022—Joint European Results of the ESSCA A and the EBS B Working Groups of the ESCD , and the GEIDAC C. Contact Dermatitis. 2026. doi:10.1111/cod.70134
BibTeX
@article{Uter2026,
author = {Uter, Wolfgang and Wilkinson, S Mark and Aerts, Olivier and Bauer, Andrea and Borrego, Leopoldo and Brans, Richard and Buhl, Timo and Dickel, Heinrich and Dugonik, Aleksandra and Filon, Francesca Larese and Arnau, Ana Giménez and Patruno, Cataldo and Pónyai, Györgyi and Gregoriou, Stamatis and Schubert, Steffen and Simon, Dagmar and Stingeni, Luca and Valiukevičienė, Skaidra and Weisshaar, Elke and Werfel, Thomas and Gonçalo, Margarida and Schuttelaar, Marie-L A and ESSCAA and EBSB ESCD Working Groups, and the GEIDACC, ESSCAA and EBSB ESCD Working Groups, and the GEIDACC},
title = {Patch Test Results With the European Baseline Series, 2021/2022—Joint European Results of the ESSCA A and the EBS B Working Groups of the ESCD , and the GEIDAC C},
journal = {Contact Dermatitis},
year = {2026},
doi = {10.1111/cod.70134}
}
EUVIMED